Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 16/20 | 0.62 |
| ▸ | PGR | P06401 | 5/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.55 |
| ▸ | SMO | Q99835 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29573526 | 1.00 | NR3C1 (0.62) | NR3C1PGRCYP11B2SMO | |
| SCHEMBL13836976 | 0.90 | CHEK1 (0.50) | NR3C1PGRCYP11B2 | |
| SCHEMBL5135413 | 0.86 | CYP11B2 (0.71) | NR3C1PGRCYP11B2 | |
| SCHEMBL30127430 | 0.83 | NR3C1 (0.54) | NR3C1PGRCYP11B2SMO | |
| SCHEMBL21295429 | 0.83 | NR3C1 (0.54) | NR3C1PGRCYP11B2SMO | |
| SCHEMBL4629474 | 0.83 | CYP11B2 (0.46) | NR3C1PGRCYP11B2 | |
| SCHEMBL25269630 | 0.82 | CYP11B2 (0.47) | NR3C1PGRCYP11B2SMO | |
| SCHEMBL22225746 | 0.82 | NR3C1 (0.74) | NR3C1PGRCYP11B2 | |
| SCHEMBL20603941 | 0.81 | CYP11B2 (0.52) | NR3C1PGRCYP11B2 | |
| SCHEMBL413100 | 0.81 | NR3C1 (0.62) | NR3C1PGRCYP11B2SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331034-B2 | Substituted pyrrolidine amides V | GRUENENTHAL GMBH (DE) | 2025-06-17 | — | — | US | disclosed |
| US-20220106294-A1 | SUBSTITUTED PYRROLIDINE AMIDES V | GRUENENTHAL GMBH (DE) | 2022-04-07 | — | — | US | disclosed |
| US-20220106294-A1 | SUBSTITUTED PYRROLIDINE AMIDES V | GRUENENTHAL GMBH (DE) | 2022-04-07 | — | — | US | disclosed |
| WO-2020254552-A2 | SUBSTITUTED PYRROLIDINE AMIDES V | Grünenthal GmbH (DE) | 2020-12-24 | — | — | WO | disclosed |
| EP-3087067-B1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-24 | — | — | EP | disclosed |
| US-9624170-B2 | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20160318864-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-03 | — | — | US | disclosed |
| EP-3087067-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2016-11-02 | — | — | EP | disclosed |
| WO-2015099196-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-02 | — | — | WO | disclosed |
| US-8658637-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-25 | — | — | US | disclosed |
| EP-2094692-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008124665-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124665-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | WO | disclosed |
| US-20080227820-A1 | CYCLIC PHENYL-SUBSTITUTED INDAZOLS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AG (DE) | 2008-09-18 | — | — | US | disclosed |
| WO-2008070507-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070507-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008057856-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057856-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008052808-A1 | CYCLIC PHENYL-SUBSTITUTED INDAZOLS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | WO | disclosed |
| EP-1917963-A1 | Cyclic phenyl-substituted indazols, a process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106294-A1 | SUBSTITUTED PYRROLIDINE AMIDES V | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 32/4885CYP11B2 21/4885 |
| US-20160318864-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, PNLIP, LYPLAL1 | NR3C1 3586/4885PGR 2386/4885CYP11B2 3069/4885 |
| US-12331034-B2 | Substituted pyrrolidine amides V | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 32/4885CYP11B2 21/4885 |
| US-20080227820-A1 | CYCLIC PHENYL-SUBSTITUTED INDAZOLS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | PTGIS, PTGS1, PTGES | NR3C1 865/4885PGR 897/4885CYP11B2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.